Integrated Drug Profiling and CRISPR Screening Identify BCR::ABL1-Independent Vulnerabilities in Chronic Myeloid Leukemia

The authors performed ex vivo drug screening of CML CD34+ leukemic stem/progenitor cells using 100 single drugs and tyrosine kinase inhibitor-drug combinations and identify sensitivities to Wee1, MDM2, and BCL2 inhibitors.